key: cord-0983472-9f73ys2g
authors: Saia, Rafael Simone; Giusti, Humberto; Silva, Fábio Luís; Pedroso, Karina de Jesus Bonicenha; Auxiliadora-Martins, Maria; Morejón, Karen Mirna Loro; Degiovani, Augusto Marcussi; Cadelca, Márcia Regina; Basile-Filho, Anibal
title: Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
date: 2021-09-28
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.09.051
sha: 5abef807daddaa8b15d472a582d7334013376e48
doc_id: 983472
cord_uid: 9f73ys2g

Objectives SARS-CoV-2 exhibits tropism for the gastrointestinal tract, however lesions in enterocytes and their correlation with disease severity and patient prognosis are still unknown. Methods SARS-CoV-2 patients were enrolled in five medical centres in the São Paulo State, Brazil. Clinical characteristics and laboratory findings of patients were recorded. At admission, 7th and 14th day of hospitalisation, plasma and urine samples were collected. The levels of cytokines (IFN-γ, IL-6 and TNF-α) and the biomarker intestinal fatty acid-binding protein (I-FABP) were measured. Results COVID-19 patients displayed ≈48-, 74- and 125-fold increased urinary I-FABP levels at admission (n=283; p<0.001), 7th (n=142; p<0.01) and 14th day (n=75; p<0.01) of hospitalisation, respectively. Critically ill patients and nonsurvivors showed higher I-FABP concentrations compared to those in the infirmary and survivors, respectively, within the same hospital stay periods. At admission, infected patients demonstrated enhanced production of plasma IFN-γ and IL-6. The ROC curve suggested I-FABP as a biomarker for disease severity of COVID-19 at admission (p<0.0001; Youden index=6.89; AUC=0.699). Patients with I-FABP≥6.89 showed higher IL-6 and C-reactive protein levels (p<0.001) at admission, as well as prolonged length of hospital stay. Conclusions Our findings revealed damage to enterocytes in SARS-CoV-2 infection, which is associated to illness severity, poor prognosis and exacerbated inflammatory response.

 SARS-CoV-2 induces long-lasting loss of enterocyte membrane integrity  Elevated urinary I-FABP levels are associated with disease severity and poor outcome  Damage to enterocytes is correlated to high IL-6 production

Gastrointestinal (GI) symptoms including vomiting, abdominal discomfort and diarrhoea have been reported in coronavirus infections at the onset of hospitalisation, affecting 10-30% of patients (Parasa et al., 2020) . SARS-CoV-2 RNA has been detected in faeces and stomach, duodenum and colon biopsies (Lin et al., 2020; Zhao et al., 2020) . COVID-19 patients with ongoing diarrhoea have displayed enhanced concentration of faecal calprotectin (a marker of gut inflammation), as well as systemic interleukin (IL)-6 production, regardless of the viral load (Effenberger et al., 2020) .

Although SARS-CoV-2 exhibits tropism for the GI tract, it remains unknown whether lesions in the intestinal epithelium occur.

Intestinal fatty acid-binding protein (I-FABP) is a cytosolic protein expressed in mature enterocytes of the small and large intestines (Pelsers et al., 2003) . A basal level of urinary I-FABP represents the physiological turnover rate of the epithelium, whilst its increment may indicate enterocytes cell damage. In sepsis and IBD, the increased urinary concentration of I-FABP has been confirmed as a reliable biomarker and predictor of disease reactivation, worse prognosis and clinical complications (Ho et al., 2020) . Therefore, our study assessed the levels of I-FABP in hospitalised patients with SARS-CoV-2 infection and investigated its role as a predictor of disease severity and poor prognosis.

This prospective cohort study enrolled 283 inpatients from five medical centres Nonsurvivors showed higher number of underlying comorbidities (cardiovascular and pulmonary diseases, diabetes, degenerative and malignancies), as well as deviations of the laboratory parameters (anaemia, leucocytosis, lymphocytopenia, D-dimers, CRP, LDH, serum creatinine and urea), requirement of mechanic ventilation and intensive care at admission. At 7 th and 14 th day of hospitalisation, aging, pre-existing diseases, leucocytosis and need for mechanic ventilation were relevant factors in nonsurvivor patients.

Noteworthy, COVID-19 patients displayed ≈48-, 74-and 125-fold increased urinary I-FABP levels at admission, 7 th and 14 th day of hospitalisation, respectively ( Figure 1A ; p<0.001). Critically ill patients showed higher I-FABP concentrations compared to those in the infirmary within the same hospital stay periods ( Figure 1B) .

Likewise, nonsurvivor patients were distinguished by increased I-FABP levels in contrast to survivors (Figure 1C ). At admission, the inflammatory response was characterised by augmented plasma IFN-γ and IL-6 levels in SARS-CoV-2 patients ( Figure 1D) . Interestingly, urinary IL-6 concentrations were elevated in infected patients and nonsurvivors ( Figure 1E ). The ROC analysis indicated I-FABP as a good biomarker for disease severity, predictor for poor prognosis of COVID-19 at admission ( Figure 1F ; Youden index=6.89; p<0.0001) and prolonged hospital stay ( Figure 1G ).

Patients with I-FABP≥6.89 ng/mg showed higher plasma and urine IL-6 and serum CRP concentrations, suggesting an interaction between inflammation and damage to enterocytes ( Figure 1G ).

Epithelial cells from ileum and colon express ACE2, the host cell entry receptor of coronaviruses, invading them for replication (Hoffmann et al., 2020) and shedding virions for several weeks after the onset of the illness (Zhao et al., 2020). Enteric symptoms reflect a break in the gut mucosa homeostasis, triggering the immune response and "cytokine release syndrome" (Effenberger et al., 2020) . Soluble protein mediators, such as IFN-γ and IL-6, are key drivers of the inflammation-associated enterocyte damage and also responsible for increased gut mucosal permeability (Neurath, 2014; Wang et al., 2001) . Indeed, our findings confirmed the detrimental contribution of SARS-CoV-2 to the loss of enterocyte membrane integrity, which is correlated with increased I-FABP levels (up to the 14 th day after hospitalisation) and patient clinical condition. Moreover, patients whose I-FABP≥6.89 ng/mg also showed Degenerative disorders 0 (0) γ 1 (0.5) 9 (8.8) c 0 (0) 4 (6.1) a 0 (0) 0 (0) Neurological diseases 1 (2.7) 12 (6.6) 6 (5.9) 8 (10.5) 7 (10.6) 5 (11.9) 4 (12. Legend: ALT (alanine aminotransferase); AST (aspartate aminotransferase); BMI (body mass index); CRP (C-reactive protein); Ethnicity (C = Caucasian, AA = Afro American, H = Hispanic); HR (heart rate); ICU (intensive care unit); LDH (lactate dehydrogenase); MAP (mean arterial pressure); PaCO 2 (partial pressure of carbon dioxide in arterial blood); PaO 2 (partial pressure of oxygen in arterial blood); SaO 2 (arterial oxygen saturation 

Faecal calprotectin indicates intestinal inflammation in COVID-19

A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Cytokines in inflammatory bowel disease

Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility

Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia

Serum urea